Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Nutrients ; 13(12)2021 Dec 09.
Artículo en Inglés | MEDLINE | ID: mdl-34959964

RESUMEN

BACKGROUND: In people living with HIV, combination antiretroviral therapy (cART) reduces the risk of death, but the persistent immune-deficient state predisposes them to pneumococcal infections. Current guidelines encourage administering pneumococcal vaccine Prevenar 13 to patients living with HIV. Since probiotic supplementation could act as adjuvants and improve vaccine immunogenicity by modulating gut microbiota, the present study aimed to assess whether the effect of a formulation containing a combination of specific probiotics (Vivomixx®) could improve the immune response to 13-valent pneumococcal conjugate vaccine (PCV13) in adult people living with HIV. METHODS: Thirty patients who were clinically stable and virologically suppressed, without opportunistic infections during this time and no ART changes in the 12 months before the study started were enrolled. Patients were divided into two groups: (1) received a placebo dose and (2) received Vivomixx® (1800 billion CFU) for four weeks before and after the vaccination with a single dose of PCV13. RESULTS: Vivomixx® supplementation induced a better response to PCV13 immunization, as shown by greater change in anti-Pn CPS13 IgG and increase in salivary IgA, IL-10 and IL-8. CONCLUSIONS: Additional investigations will help to clearly and fully elucidate the optimal strains, doses, and timing of administration of probiotics to improve protection upon vaccination in immunocompromised individuals and the elderly.


Asunto(s)
Suplementos Dietéticos , Infecciones por VIH/inmunología , Inmunidad/inmunología , Vacunas Neumococicas/inmunología , Probióticos/administración & dosificación , Adulto , Anciano , Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , Humanos , Huésped Inmunocomprometido/inmunología , Inmunoglobulina A , Inmunoglobulina G , Interleucina-10 , Interleucina-8 , Masculino , Persona de Mediana Edad
2.
Urology ; 131: 196-203, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31145946

RESUMEN

OBJECTIVE: To test the prevalence and predictors of major acute cardiovascular events (MACE) after transurethral prostate surgery (TPS). MATERIAL AND METHODS: The American College of Surgeons National Surgical Quality Improvement Program database (2011-2016) was queried for patients who underwent transurethral resection of the prostate, photoselective vaporization, or laser enucleation. MACE included: cerebrovascular events, cardiac arrest, myocardial infarction, deep venous thrombosis requiring therapy, and pulmonary embolism episodes occurred up to 30 days after discharge. Univariable and multivariable logistic regression models tested MACE predictors and effect of MACE on perioperative mortality. Within covariates significant at univariable analyses a stepwise selection, based on Akaike Information Criterion values, was performed to fit the most appropriate multivariable model. RESULTS: Overall 44,939 patients were included in our analyses. Of these 365 (0.8%) had MACE within 30 days after surgery. The strongest MACE predictors were recent congestive heart failure (odds ratio [OR]: 2.1, 95% confidence interval [CI]: 1.2-3.7, P = .007), transfusions (OR: 2.5, 95% CI: 1.5-4.1, P <.001) and preoperative Systemic Inflammatory Response Syndrome or sepsis (OR: 2.6, 95% CI: 1.6-4.2, P <.001). Similarly, inpatient (OR: 2.0, 95% CI: 1.6-2.5, P <.001) and nonelective (OR: 1.5, 95% CI: 1.1-2.1, P = .012) patients experienced higher MACE rates. Perioperative mortality rates were statistical significantly higher in MACE patients (OR: 13.1, 95% CI: 8.2-21.0, P <.001). CONCLUSION: Up to 1% of patients undergoing transurethral prostate surgery experience MACE. MACE are burdened by high mortality rates (up to 14% in MACE patients). Proper patient selection and postoperative monitoring are necessary to reduce MACE incidence and mortality rates.


Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Complicaciones Posoperatorias/epidemiología , Resección Transuretral de la Próstata , Enfermedad Aguda , Anciano , Humanos , Masculino , Prevalencia
3.
Acta Diabetol ; 55(8): 805-812, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29774465

RESUMEN

AIMS: Gestational diabetes mellitus (GDM) is the most common metabolic disorder of pregnancy. The aim of the study is to compare the effect of different dosages of inositol stereoisomers supplementation on insulin resistance levels and several maternal-fetal outcomes in GDM women. METHODS: Participants were randomly allocated to receive daily: 400 mcg folic acid (control treatment), 4000 mg myo-inositol plus 400 mcg folic acid (MI treatment), 500 mg D-chiro-inositol plus 400 mcg folic acid (DCI treatment) or 1100/27.6 mg myo/D-chiro-inositol plus 400 mcg folic acid (MI plus DCI treatment). The homeostasis model assessment of insulin resistance (HOMA-IR) was measured at the diagnosis of GDM and after 8 weeks of treatment. Secondary outcomes, obstetric outcomes and any maternal or fetal complication at delivery were also collected. RESULTS: Eighty GDM women were assigned to one of the four arms of study (20 per arm). A significant delta decrease in HOMA-IR index was found in subjects of MI group without insulin therapy compared to control group (p < 0.001). A lower variation in average weight gain (at delivery vs pre-pregnancy and OGTT period) was detected in MI group vs control group (p = 0.001 and p = 0.019, respectively). Moreover, women exposed to MI and MI plus DCI required a significantly lower necessity of an intensified insulin treatment. Women of the control group had newborns with higher birth weight compared with women treated with inositol (p = 0.032). CONCLUSIONS: Our study provides interesting but preliminary results about the potential role of inositol stereoisomers supplementation in the treatment of GDM on insulin resistance levels and several maternal-fetal outcomes. Further studies are required to examine the optimal and effective dosages of different inositol supplements. CLINICAL TRIAL REG. NO.: NCT02097069, ClinicalTrial.gov.


Asunto(s)
Diabetes Gestacional/tratamiento farmacológico , Inositol/administración & dosificación , Adolescente , Adulto , Diabetes Gestacional/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inositol/química , Resistencia a la Insulina , Persona de Mediana Edad , Embarazo , Resultado del Embarazo , Estereoisomerismo , Adulto Joven
4.
J Cell Mol Med ; 22(5): 2750-2759, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29512923

RESUMEN

Gastroesophageal reflux disease (GERD), a clinical condition characterized by reflux of gastroduodenal contents in the oesophagus, has proved to demonstrate a strong link between oxidative stress and the development of GERD. Proton pump inhibitors (PPIs) have been universally accepted as first-line therapy for management of GERD. The potential benefits of electrolysed reduced water (ERW), rich in molecular hydrogen, in improving symptoms and systemic oxidative stress associated with GERD was assessed. The study was performed on 84 GERD patients undergoing control treatment (PPI + tap water) or experimental treatment (PPI + ERW) for 3 months. These patients were subjected to the GERD-Health Related Quality of Life Questionnaire as well as derivatives reactive oxigen metabolites (d-ROMs) test, biological antioxidant potential (BAP) test, superoxide anion, nitric oxide and malondialdehyde assays, which were all performed as a proxy for the oxidative/nitrosative stress and the antioxidant potential status. Spearman's correlation coefficient was used to evaluate the correlation between scores and laboratory parameters. Overall results demonstrated that an optimal oxidative balance can be restored and GERD symptoms can be reduced rapidly via the integration of ERW in GERD patients. The relative variation of heartburn and regurgitation score was significantly correlated with laboratory parameters. Thus, in the selected patients, combination treatment with PPI and ERW improves the cellular redox state leading to the improvement of the quality of life as demonstrated by the correlation analysis between laboratory parameters and GERD symptoms.


Asunto(s)
Reflujo Gastroesofágico/sangre , Reflujo Gastroesofágico/terapia , Hidrógeno/uso terapéutico , Agua/farmacología , Adulto , Anciano , Antioxidantes/metabolismo , Humanos , Persona de Mediana Edad , Oxidación-Reducción , Estrés Oxidativo/efectos de los fármacos , Inhibidores de la Bomba de Protones/uso terapéutico , Calidad de Vida , Adulto Joven
5.
Nutrients ; 7(10): 8335-47, 2015 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-26426044

RESUMEN

UNLABELLED: Inflammation persists in patients infected with HIV. Reduction of inflammatory cytokines and microbial translocation might be one way that this could be managed. PURPOSE: The anti-inflammatory properties of certain probiotic strains prompted us to investigate whether a probiotic could reduce the inflammatory index of HIV-infected patients. METHODS: The study involved 30 HIV+ males on antiretroviral therapy, who were given one bottle of fermented milk Yakult Light® containing Lactobacillus casei Shirota (LcS) twice a day for four weeks. RESULTS: The probiotic LcS was associated with an increase of T lymphocytes and a significant increase of CD56+ cells (p = 0.04). There was also a significant decrease of mRNA levels of TGFß, IL-10 and IL-12 (p < 0.001) and IL-1ß expression (p < 0.001) and an increase of serum IL-23 (p = 0.03). In addition, decreased inflammation and cardiovascular risk were observed, as shown by a reduction of cystatin C (p < 0.001). CONCLUSIONS: These data provide preliminary evidence that probiotic supplementation may modulate certain immunological parameters and some of the cytokines that were analyzed. Thus, we propose that LcS may be an inexpensive and practical strategy to support the immune function of HIV+ patients.


Asunto(s)
Citocinas/sangre , Infecciones por VIH/terapia , Probióticos/administración & dosificación , Antiinflamatorios , Antirretrovirales/uso terapéutico , Antígeno CD56/análisis , Productos Lácteos Cultivados , Humanos , Interleucina-10/sangre , Interleucina-10/genética , Interleucina-12/sangre , Interleucina-12/genética , Lacticaseibacillus casei , Recuento de Linfocitos , Masculino , ARN Mensajero/sangre , Linfocitos T/inmunología , Factor de Crecimiento Transformador beta/sangre , Factor de Crecimiento Transformador beta/genética
6.
Dermatol Surg ; 41(8): 898-902, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26218723

RESUMEN

BACKGROUND: Actinic keratoses (AKs) are a common premalignant skin condition. Many treatments are available for AKs. Photodynamic therapy (PDT) is one of the most effective treatments. However, major concerns exist on the possibility of PDT-induced DNA-mutagenesis/immunosuppression, leading to AKs recurrence/treatment failure. An extract (PLE) from the fern polypodium leucotomos reduces UV-induced immunosuppression and mutagenesis. OBJECTIVE: To assess the ability of PLE to enhance the efficacy of PDT treatment, reducing AKs recurrence on the scalp. MATERIALS AND METHODS: Thirty-four bald patients presenting at least two AKs on the scalp were alternatively assigned to two groups. Both groups underwent two PDT-sessions one-week apart. The first group began oral PLE supplementation one week after the last PDT session. Evaluation of the effect of PLE supplementation was performed by direct inspection of the bald areas, lesions count, and photodynamic diagnosis assessment at 2 and 6 months. RESULTS: Both groups were homogeneous in terms of skin phototype and previous UV exposure. Mean age was 75.7 ± 7.8 years and 76.5 ± 5.5 years, respectively. Both treatment modalities were successful in reducing AKs number (p < .001). However, PLE supplementation increased clearance rate compared with PDT alone (p = .040). CONCLUSION: Polypodium leucotomos improves PDT clearance and decreases AK recurrence rate at 6 months, suggesting its use as a complementary agent in the treatment of field cancerization.


Asunto(s)
Queratosis Actínica/tratamiento farmacológico , Fotoquimioterapia , Fitoterapia , Extractos Vegetales/uso terapéutico , Polypodium/química , Dermatosis del Cuero Cabelludo/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Ácido Aminolevulínico/análogos & derivados , Ácido Aminolevulínico/uso terapéutico , Humanos , Masculino , Fármacos Fotosensibilizantes/uso terapéutico , Recurrencia
8.
Int J STD AIDS ; 25(11): 785-92, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24469972

RESUMEN

Summary A high incidence of 25OH vitamin D deficiency has been observed in HIV-infected subjects. The objective of this study was to evaluate the effect of cholecalciferol administration on serum 25OH vitamin D levels in HIV-infected patients. This prospective cohort study included 153 HIV-positive subjects; 47 were treated with 300,000 IU intramuscular cholecalciferol, 67 with 25,000 IU oral cholecalciferol monthly, while the remaining 39 did not receive any treatment. The group treated orally had an increase of serum 25OH vitamin D concentration, changing from 15.7 ± 12.2 ng/mL to 27.4 ± 11.6 ng/mL after 10 months (T10). The group treated with intramuscular supplementation had an improvement, changing from 18.5 ± 10.5 ng/mL to 32.9.0 ± 12.2 ng/mL at T10. One-way repeated measures analysis of variance indicated a significant difference for 25OH vitamin D variation (p = 0.002) among the three groups. A significant effect of time (p < 0.001) and group × time interaction (p < 0.001) was found: at T10, 25OH vitamin D values were significantly higher in the oral and intramuscular groups with respect to the control group. Our findings showed that the supplementation with cholecalciferol in patients with HIV-infection improved 25OH vitamin D serum levels, and suggest that the two types of administration are equivalent, but are insufficient for severe forms of hypovitaminosis.


Asunto(s)
Colecalciferol/administración & dosificación , Suplementos Dietéticos , Infecciones por VIH/sangre , Deficiencia de Vitamina D/tratamiento farmacológico , Vitamina D/análogos & derivados , Vitaminas/administración & dosificación , Administración Oral , Adulto , Análisis de Varianza , Fármacos Anti-VIH/uso terapéutico , Femenino , Infecciones por VIH/tratamiento farmacológico , Humanos , Inyecciones Intramusculares , Italia/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Factores Socioeconómicos , Resultado del Tratamiento , Vitamina D/sangre , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/epidemiología
9.
Anticancer Res ; 33(10): 4557-66, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24123031

RESUMEN

AIM: To evaluate survival outcomes of patients in pStage II-III rectal cancer treated with adjuvant 5-fluorouracil-based radiochemotherapy and to retrospectively analyze the impact of prognostic variables on local control, metastasis-free survival and cause-specific survival. PATIENTS AND METHODS: A total of 1,338 patients, treated between 1985-2005 for locally advanced rectal cancer, who underwent surgery and postoperative 5-fluorouracil-based chemoradiation, were selected. RESULTS: The actuarial 5- and 10-year outcomes were: local control 87.0%-84.1%, disease-free survival 61.6%-52.1%, metastasis-free survival 72.0%-67.2%, cause-specific survival 70.4%-57.5%, and overall survival 63.8%-53.4%. Better outcomes were observed in patients with IIA, IIIA stage. Multivariate analyses showed that variables significantly affecting metastasis-free survival were pT4 and pN2, while for cancer-specific survival those variables were age >65 years, pT4, pN1, pN2, distal tumors and number of lymph nodes removed ≤ 12. CONCLUSION: This study confirmed that among stage II-III rectal cancer patients there are subgroups of patients with different clinical outcomes.


Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Fluorouracilo/uso terapéutico , Neoplasias del Recto/terapia , Quimioradioterapia , Supervivencia sin Enfermedad , Humanos , Estimación de Kaplan-Meier , Metástasis Linfática , Periodo Posoperatorio , Pronóstico , Neoplasias del Recto/mortalidad , Neoplasias del Recto/patología , Estudios Retrospectivos , Resultado del Tratamiento
10.
Mil Med ; 172(2): 140-3, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17357766

RESUMEN

This cross-sectional study evaluated the stress levels in Italian military personnel involved in a peacekeeping (PK) mission in Afghanistan and a homogeneous group stationed in Italy (SI group). The study was performed from April 2004 to June 2004 in a sample of 160 long-time, career volunteers of the Rossi Barracks of the Alpini di L'Aquila (Italy) (SI group, n=120; PK group, n=40). A 10-item, self-evaluation questionnaire proposed in the U.N. Stress Management Booklet was administered to each volunteer. The total item score (TIS) values for the 10 items for the two groups were calculated. These values were greater for the PK group than for the SI group for all 10 items. The TIS values were grouped into three classes of symptoms, anxiety symptoms (items 1-4), stress-induced depression (items 5-7), and posttraumatic stress (items 8-10). The class total item score (CTIS) values were then calculated as the sum of the respective TIS values. The three CTIS values for the PK group were greater than those for the SI group. In particular, the anxiety CTIS was 72 points greater in the PK group (p < 0.001). Therefore, the peacekeepers were inclined to have a greater increase in anxiety symptoms. Consequently, antipanic techniques could be used to reduce anxiety and progressive muscular relaxation training, an important preventive relaxation technique, to face stressors and to reduce clinical anxiety.


Asunto(s)
Personal Militar/psicología , Terapia por Relajación , Estrés Psicológico/terapia , Guerra , Adulto , Afganistán , Ansiedad/diagnóstico , Ansiedad/etiología , Ansiedad/prevención & control , Estudios Transversales , Depresión/diagnóstico , Depresión/etiología , Depresión/prevención & control , Estudios de Seguimiento , Humanos , Italia/epidemiología , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Estrés Psicológico/complicaciones , Estrés Psicológico/epidemiología , Encuestas y Cuestionarios , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA